Pathogenic Fungal Infections in Cancer and Transplant Patients
Share This Topical Collection
Editors
Prof. Dr. Issam I Raad
Prof. Dr. Issam I Raad
E-Mail
Website
Collection Editor
Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: fungal infections in cancer and SCT; CLABSI prevention and management; febrile neutropenia; procalcitonin and biomarkers of sepsis in cancer
Dr. Marjorie Vieira Batista
Dr. Marjorie Vieira Batista
E-Mail
Collection Editor
Department of Infectious Diseases, AC Camargo Cancer Center, São Paulo 01509-010, SP, Brazil
Interests: fungal infection; hematopoietic stem cells; stem cell transplantation
Topical Collection Information
Dear Colleagues,
This Topical Collection, entitled "Pathogenic Fungal Infections in Cancer and Transplant Patients", aims to present recent research on any aspect of invasive fungal infections in immunocompromised cancer and stem cell and solid organ transplant patients. Patients with prior CAR-T cell intervention are also of interest. This field has seen major advances over the last 5 to 10 years, which will be highlighted in this Topical Collection. Some of the focal areas include, but are not limited to, the following:
- The changing epidemiology and risk factors of fungal infections in cancer and transplant patients.
- Pathogenesis of fungal infections in cancer and transplant patients.
- Immunology of fungal infections in cancer and transplant patients.
- Biofilm and pathogenic fungal infections in cancer and transplant patients.
- Advances in the diagnosis, prevention, management, and treatment of fungal infections in cancer and transplant patients.
Reviews, original research, and communications are welcome.
Prof. Dr. Issam I Raad
Dr. Marjorie Vieira Batista
Collection Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript.
The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs).
Submitted papers should be well formatted and use good English. Authors may use MDPI's
English editing service prior to publication or during author revisions.
Keywords
- pathogenic fungal infections
- fungal infections in cancer
- fungal infections in stem cell transplant
- fungal infections in solid organ transplant
Published Papers (1 paper)
2023
Open AccessArticle
Invasive Aspergillosis among Lung Transplant Recipients during Time Periods with Universal and Targeted Antifungal Prophylaxis—A Nationwide Cohort Study
by
Cornelia Geisler Crone, Signe Marie Wulff, Bruno Ledergerber, Jannik Helweg-Larsen, Pia Bredahl, Maiken Cavling Arendrup, Michael Perch and Marie Helleberg
Cited by 1 | Viewed by 1801
Abstract
The optimal prevention strategy for invasive aspergillosis (IA) in lung transplant recipients (LTXr) is unknown. In 2016, the Danish guidelines were changed from universal to targeted IA prophylaxis. Previously, we found higher rates of adverse events in the universal prophylaxis period. In a
[...] Read more.
The optimal prevention strategy for invasive aspergillosis (IA) in lung transplant recipients (LTXr) is unknown. In 2016, the Danish guidelines were changed from universal to targeted IA prophylaxis. Previously, we found higher rates of adverse events in the universal prophylaxis period. In a Danish nationwide study including LTXr, for 2010–2019, we compared IA rates in time periods with universal vs. targeted prophylaxis and during person-time with vs. person-time without antifungal prophylaxis. IA hazard rates were analyzed in multivariable Cox models with adjustment for time after LTX. Among 295 LTXr, antifungal prophylaxis was initiated in 183/193 and 6/102 during the universal and targeted period, respectively. During the universal period, 62% discontinued prophylaxis prematurely. The median time on prophylaxis was 37 days (IQR 11–84). IA was diagnosed in 27/193 (14%) vs. 15/102 (15%) LTXr in the universal vs. targeted period, with an adjusted hazard ratio (aHR) of 0.94 (95% CI 0.49–1.82). The aHR of IA during person-time with vs. person-time without antifungal prophylaxis was 0.36 (95% CI 0.12–1.02). No difference in IA was found during periods with universal vs. targeted prophylaxis. Prophylaxis was protective of IA when taken. Targeted prophylaxis may be preferred over universal due to comparable IA rates and lower rates of adverse events.
Full article
►▼
Show Figures
